Skip to main content
< Back to news
From left to right: Jordi Carrera and Rafael Bru, founders of Stat-Diagnostica (Foto: Parc Científic de Barcelona).

Stat-Diagnostica attracts Siemens Venture Capital as a new investor

Medical diagnostics company Stat-Diagnostica, based at the Barcelona Science Park, has closed an extension of its Series C financing with Siemens Venture Capital. Led by Gilde Healthcare, the Series C financing round also drew participation from existing investors, including Kurma Partners, Ysios Capital, Idinvest Partners, Boehringer Ingelheim Venture Fund, Caixa Capital Risc, and Axis. The additional proceeds will be used to support the 2017 European launch of its DiagCORE Near Patient Testing system. 


“Stat-Diagnostica has an exciting technology that could significantly advance the diagnosis and triage of infectious diseases. We are impressed with the team and look forward to working with them in bringing DiagCORE to clinicians treating patients around the world,” said Ralf Schnell, CEO of Siemens Venture Capital.

DiagCORE is a fully integrated molecular and immunoassay diagnostics system that delivers lab-like performance in just one step, providing unrivaled usability for true walk-away diagnostics. DiagCORE performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48-multiplex capabilities via real-time PCR. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type. DiagCORE’s rapid performance is expected to improve clinical decision making and deliver better patient management and cost savings to the healthcare system.

“We are delighted that Siemens Venture Capital has become part of our investor base. Their participation is a terrific validation of the company’s vision and the work of our entire team,” said Jordi Carrera, CEO and co-founder of Stat-Diagnostica. “Together, we believe in DiagCORE’s unique potential to meet the changing and fast growing molecular diagnostics market dynamics.”

Stat-Diagnostica plans to target a range of decentralized testing environments with DiagCORE, including critical care and emergency medicine units within hospitals. The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.

Stat-Diagnostica –founded at the Barcelona Science Park in 2010 by Jordi Carrera and Rafael Bru– is focused on the development of Near Patient Testing solutions where fast and accurate diagnostic results are needed. Since its foundation, the company has acquired 44 million euros since it was founded in 2010, of which over half comes from international investors. The latest capital contributed by Siemens Venture Capital increase will be used to complete all the processes necessary to receive approval for the DiagCORE platform, which the company has been developing for five years.